Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Computer Models Help to Develop Improved Gene Therapy Vectors

By BiotechDaily International staff writers
Posted on 29 Aug 2013
Print article
Image: Electron micrograph of adeno-associated viruses (AAVs) (Photo courtesy of Dr. Graham Beards at en.wikipedia).
Image: Electron micrograph of adeno-associated viruses (AAVs) (Photo courtesy of Dr. Graham Beards at en.wikipedia).
Investigators in the field of gene therapy have used an advanced computer algorithm to predict how different adeno-associated viruses (AAVs) can be combined to form the optimum carriers of therapeutic genetic material.

AAVs are small viruses that infect humans and some other primate species. AAVs are not currently known to cause disease, and the virus induces a very mild immune response. Gene therapy vectors using AAV can infect both dividing and quiescent cells and persist in an extrachromosomal state without integrating into the genome of the host cell. These features make AAV an attractive candidate for creating viral vectors for gene therapy.

To develop quantitative design principles for guiding site-directed recombination of AAV capsids, investigators at Rice University (Houston, TX, USA) examined how capsid structural perturbations predicted by the SCHEMA algorithm correlated with experimental measurements of disruption in 17 chimeric capsid proteins.

They reported in the July 31, 2013, online addition of journal ACS Synthetic Biology that in a chimera population created by recombining AAV serotypes two and four, protection of viral genomes and cellular transduction were inversely related to calculated disruption of the capsid structure. The investigators did not observe a correlation between genome packaging and calculated structural disruption; a majority of the chimeric capsid proteins formed at least partially assembled capsids and more than half-packaged genomes, including those with the highest SCHEMA disruption. Thus, the SCHEMA algorithm should be useful for delineating quantitative design principles to guide the creation of libraries enriched in genome-protecting virus nanoparticles that can effectively transduce cells.

“Gene therapy shows promise in the treatment of not only genetic disorders but also cancer and cardiovascular diseases,” said senior author Dr. Junghae Suh, assistant professor of bioengineering at Rice University. “But you need a mechanism to get the correct gene into the human body and to the target cells. To do that, people use gene vectors, and viruses encompass the largest category of vectors. They have naturally evolved to deliver genes into the body. Our goal is to reprogram them to target specific organs or tissues.”

“The big challenge is to go about this in a rational manner,” said Dr. Suh. “People have done a lot of work to solve the structure of viruses. We know what they look like. The question is: How can we use that information to guide the design of our viral vectors?”

Related Links:
Rice University


Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.